Disparities in the diagnosis and treatment of colorectal cancer among patients with disabilities

IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY World Journal of Gastrointestinal Oncology Pub Date : 2024-07-15 DOI:10.4251/wjgo.v16.i7.2925
Ki Bae Kim, D. Shin, K. E. Yeob, S. Y. Kim, J. Han, Seon Mee Park, Jong Heon Park, Jong Hyock Park
{"title":"Disparities in the diagnosis and treatment of colorectal cancer among patients with disabilities","authors":"Ki Bae Kim, D. Shin, K. E. Yeob, S. Y. Kim, J. Han, Seon Mee Park, Jong Heon Park, Jong Hyock Park","doi":"10.4251/wjgo.v16.i7.2925","DOIUrl":null,"url":null,"abstract":"BACKGROUND\n Little is known about disparities in diagnosis and treatment among colorectal cancer (CRC) patients with and without disabilities.\n AIM\n To investigate the patterns of diagnosis, treatment, and survival for people with and without disabilities who had CRC.\n METHODS\n We performed a retrospective analysis using the Korean National Health Insurance Service database, disability registration data, and Korean Central Cancer Registry data. The analysis included 21449 patients with disabilities who were diagnosed with CRC and 86492 control patients diagnosed with CRC.\n RESULTS\n The overall distribution of CRC stage was not affected by disability status. Subjects with disabilities were less likely than those without disabilities to undergo surgery [adjusted odds ratio (aOR): 0.85; 95% confidence interval (95%CI): 0.82-0.88], chemotherapy (aOR: 0.84; 95%CI: 0.81-0.87), or radiotherapy (aOR: 0.90; 95%CI: 0.84-0.95). The rate of no treatment was higher in patients with disabilities than in those without disabilities (aOR: 1.48; 95%CI: 1.41-1.55). The overall mortality rate was higher in patients with disabilities [adjusted hazard ratio (aHR): 1.24; 95%CI: 1.22-1.28], particularly severe disabilities (aHR: 1.57; 95%CI: 1.51-1.63), than in those without disabilities.\n CONCLUSION\n Patients with severe disabilities tended to have a late or unknown diagnosis. Patients with CRC and disabilities had lower rates of treatment with almost all modalities compared with those without disabilities. During the follow-up period, the mortality rate was higher in patients with disabilities than in those without disabilities. The diagnosis and treatment of CRC need improvement in patients with disabilities.","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Gastrointestinal Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4251/wjgo.v16.i7.2925","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

BACKGROUND Little is known about disparities in diagnosis and treatment among colorectal cancer (CRC) patients with and without disabilities. AIM To investigate the patterns of diagnosis, treatment, and survival for people with and without disabilities who had CRC. METHODS We performed a retrospective analysis using the Korean National Health Insurance Service database, disability registration data, and Korean Central Cancer Registry data. The analysis included 21449 patients with disabilities who were diagnosed with CRC and 86492 control patients diagnosed with CRC. RESULTS The overall distribution of CRC stage was not affected by disability status. Subjects with disabilities were less likely than those without disabilities to undergo surgery [adjusted odds ratio (aOR): 0.85; 95% confidence interval (95%CI): 0.82-0.88], chemotherapy (aOR: 0.84; 95%CI: 0.81-0.87), or radiotherapy (aOR: 0.90; 95%CI: 0.84-0.95). The rate of no treatment was higher in patients with disabilities than in those without disabilities (aOR: 1.48; 95%CI: 1.41-1.55). The overall mortality rate was higher in patients with disabilities [adjusted hazard ratio (aHR): 1.24; 95%CI: 1.22-1.28], particularly severe disabilities (aHR: 1.57; 95%CI: 1.51-1.63), than in those without disabilities. CONCLUSION Patients with severe disabilities tended to have a late or unknown diagnosis. Patients with CRC and disabilities had lower rates of treatment with almost all modalities compared with those without disabilities. During the follow-up period, the mortality rate was higher in patients with disabilities than in those without disabilities. The diagnosis and treatment of CRC need improvement in patients with disabilities.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
残疾患者在诊断和治疗结直肠癌方面的差异
背景 对有残疾和无残疾的结直肠癌(CRC)患者在诊断和治疗方面的差异知之甚少。目的 调查患有 CRC 的残疾人和非残疾人的诊断、治疗和生存模式。方法 我们利用韩国国民健康保险服务数据库、残疾登记数据和韩国中央癌症登记数据进行了回顾性分析。分析对象包括 21449 名确诊为 CRC 的残疾患者和 86492 名确诊为 CRC 的对照组患者。结果 CRC 分期的总体分布不受残疾状况的影响。与非残疾患者相比,残疾患者接受手术[调整后的几率比(aOR):0.85;95%置信区间(95%CI):0.82-0.88]、化疗(aOR:0.84;95%CI:0.81-0.87)或放疗(aOR:0.90;95%CI:0.84-0.95)的几率较低。残疾患者未接受治疗的比例高于非残疾患者(aOR:1.48;95%CI:1.41-1.55)。与非残疾患者相比,残疾患者的总死亡率更高[调整后危险比(aHR):1.24;95%CI:1.22-1.28],尤其是重度残疾患者(aHR:1.57;95%CI:1.51-1.63)。结论 有严重残疾的患者往往诊断较晚或诊断不明。与非残疾患者相比,CRC和残疾患者接受几乎所有方式治疗的比例都较低。在随访期间,残疾患者的死亡率高于非残疾患者。残疾患者的 CRC 诊断和治疗需要改进。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
World Journal of Gastrointestinal Oncology
World Journal of Gastrointestinal Oncology Medicine-Gastroenterology
CiteScore
4.20
自引率
3.30%
发文量
1082
期刊介绍: The World Journal of Gastrointestinal Oncology (WJGO) is a leading academic journal devoted to reporting the latest, cutting-edge research progress and findings of basic research and clinical practice in the field of gastrointestinal oncology.
期刊最新文献
Early diagnosis of esophageal cancer: How to put "early detection" into effect? Effect of acacetin on inhibition of apoptosis in Helicobacter pylori-infected gastric epithelial cell line. Effect of perioperative chemotherapy on resection of isolated pulmonary metastases from colorectal cancer: A single center experience. Efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer according to programmed cell death ligand 1. Efficacy of hepatic arterial infusion chemotherapy and its combination strategies for advanced hepatocellular carcinoma: A network meta-analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1